9 May 2023
From left to right:
- Mr. Katsuhiro Nozaki, Head of JPC Banking Division 1
- Mr. Bunsei Okubo, Krungsri Deputy Head of JPC/MNC Banking
- Mr. Yoshiyuki Horio, Krungsri Head of JPC/MNC Banking
- Mr. Nattapan Nimmanphatcharin, President of Eisai (Thailand)
- Mr. Wichit Panichyajinda, Hospital Business Unit Head of Eisai (Thailand)
- Ms. Ratanaporn Thangthanakul, Human Resource Development of Eisai (Thailand)
Bangkok (9 May 2023) –
Krungsri (Bank of Ayudhya PCL) and Eisai (Thailand) Marketing Co. Ltd. (Eisai Thailand), a leading pharmaceutical company in research and development of Alzheimer’s disease treatments, announced today that they collaborate to create the ecosystem and financial solutions related to treatments for of Alzheimer’s disease patients, particularly those in the early stage, to address the challenges of an aging society in Thailand. The two organizations recently signed a Memorandum of Understanding (MoU) to promote understanding about the prevention of the Alzheimer’s disease and the access to treatment of Alzheimer’s disease and dementia in Thailand. The signing of the MoU marked the first-ever collaboration between the pharmaceutical company creating Alzheimer’s disease treatments and the financial institution to improve the quality of life in the Thai society.
Mr. Yoshiyuki Horio, Krungsri Head of JPC/MNC Banking, said, “The trend of aging society is one of the megatrends and emerging phenomenon worldwide, including Thailand, which brings about various challenges due to the deterioration of the body and health problems, particularly the prevalence of Alzheimer’s disease and dementia. This results in limited access to and high costs of medication care and treatment services while the Alzheimer’s disease patients need long-term care. Krungsri has recognized the emerging challenges and wants to be part of the solutions to such issues. Accordingly, we have been partnering with Eisai Thailand in developing the innovations and solutions for treating Alzheimer’s disease patients, particularly those with the early-stage of Alzheimer’s disease, and building a strong ecosystem of Alzheimer’s disease treatments in collaborations with related agencies. Moreover, Krungsri is exploring the opportunities and possibility of financial products and services that specifically cover the treatment of Alzheimer’s disease and dementia, with the aim of facilitating patients’ access to medical treatment more easily in the near future and reducing the long-term burdens on both patients and their families, which is in line with Krungsri’s current Medium-Term Business Plan (2021-2023) in establishing key ecosystem buildings covering the living ecosystem as well as fostering a sustainable development under the ESG framework especially in the social aspect.”
Mr. Nattapan Nimmanphatcharin, President of Eisai (Thailand) said, “According to research results, by the year 2050, the number of Alzheimer’s disease patients in Thailand will reach more than one million people. Being the leader in the Alzheimer’s disease treatment industry, Eisai has strived to conduct the research and development of pharmaceutical products that help improve the quality of life of at-risk patients or patients with the early stage of Alzheimer’s disease in accordance with Eisai’s human health care (hhc) concept. However, the impacts derived from Alzheimer’s disease are not only confined to Alzheimer’s disease patients but also are also extended to the way of life of their families, the people around them, and the society as a whole. Therefore, having accurate knowledge and understanding about dementia is the core foundation leading to the diagnosis, provision of medical care, and preparation for addressing the problems that will arise in the future. For this reason, Eisai Thailand forms partnership with many organizations and agencies in setting up the health ecosystems in relation to the Alzheimer’s disease focusing on providing full cycle healthcare services to the patients, their families and the general public. The first phase of operations will begin with building social awareness on taking care of the elderly and those suffering from Alzheimer’s disease and dementia as well as developing a digital platform for patients and caregivers to promote knowledge and understanding about the guidelines on providing care and treatment including the prevention of Alzheimer’s disease and dementia in Thailand. Eisai Thailand sincerely hopes that the collaboration with Krungsri and relevant strategic partners will help the Alzheimer’s disease patients to be self-reliant and live a better-quality life as well as reduce the problems that may exert an unfavorable impact on their families, caregivers and the surrounding society. This will certainly drive the Thai society towards sustainable development goals in the future.”
The MoU was recently signed between Krungsri, represented by Mr. Yoshiyuki Horio, Head of JPC/MNC Banking, Mr. Bunsei Okubo, Deputy Head of JPC/MNC Banking, and Mr. Katsuhiro Nozaki, Head of JPC Banking Division 1; and Eisai (Thailand), represented by Mr. Nattapan Nimmanphatcharin, President, Mr. Wichit Panichyajinda, Hospital Business Unit Head, and Ms. Ratanaporn Thangthanakul, Human Resource Development. The collaboration aims to promote a better understanding of the prevention of Alzheimer’s disease and dementia, as well as to improve access to treatments in Thailand.